Clinical Trial Update: A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial investigating Ethyl Eicosapentaenoic Acid with [11C]PBR-28 in bipolar disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Ethyl Eicosapentaenoic Acid (ethyl eicosapentaenoic acid)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Bipolar Disorder | Phase 4 | Status: WITHDRAWN